2noj: Difference between revisions
From Proteopedia
Jump to navigationJump to search
New page: left|200px<br /> <applet load="2noj" size="450" color="white" frame="true" align="right" spinBox="true" caption="2noj, resolution 2.70Å" /> '''Crystal structure o... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2noj. | [[Image:2noj.jpg|left|200px]]<br /><applet load="2noj" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="2noj" size=" | |||
caption="2noj, resolution 2.70Å" /> | caption="2noj, resolution 2.70Å" /> | ||
'''Crystal structure of Ehp / C3d complex'''<br /> | '''Crystal structure of Ehp / C3d complex'''<br /> | ||
| Line 6: | Line 5: | ||
==Overview== | ==Overview== | ||
We report here the discovery and characterization of Ehp, a new secreted, Staphylococcus aureus protein that potently inhibits the alternative, complement activation pathway. Ehp was identified through a genomic scan, as an uncharacterized secreted protein from S. aureus, and immunoblotting, of conditioned S. aureus culture medium revealed that the Ehp protein was, secreted at the highest levels during log-phase bacterial growth. The, mature Ehp polypeptide is composed of 80 residues and is 44% identical to, the complement inhibitory domain of S. aureus Efb (extracellular, fibrinogen-binding protein). We observed preferential binding by Ehp to, native and hydrolyzed C3 relative to fully active C3b and found that Ehp, formed a subnanomolar affinity complex with these various forms of C3 by, binding to its thioester-containing C3d domain. Site-directed mutagenesis, demonstrated that Arg(75) and Asn(82) are important in forming the Ehp.C3d, complex, but loss of these side chains did not completely disrupt Ehp/C3d, binding. This suggested the presence of a second C3d-binding site in Ehp, which was mapped to the proximity of Ehp Asn(63). Further molecular level, details of the Ehp/C3d interaction were revealed by solving the 2.7-A, crystal structure of an Ehp.C3d complex in which the low affinity site had, been mutationally inactivated. Ehp potently inhibited C3b deposition onto, sensitized surfaces by the alternative complement activation pathway. This, inhibition was directly related to Ehp/C3d binding and was more potent, than that seen for Efb-C. An altered conformation in Ehp-bound C3 was, detected by monoclonal antibody C3-9, which is specific for a neoantigen, exposed in activated forms of C3. Our results suggest that increased, inhibitory potency of Ehp relative to Efb-C is derived from the second, C3-binding site in this new protein. | We report here the discovery and characterization of Ehp, a new secreted, Staphylococcus aureus protein that potently inhibits the alternative, complement activation pathway. Ehp was identified through a genomic scan, as an uncharacterized secreted protein from S. aureus, and immunoblotting, of conditioned S. aureus culture medium revealed that the Ehp protein was, secreted at the highest levels during log-phase bacterial growth. The, mature Ehp polypeptide is composed of 80 residues and is 44% identical to, the complement inhibitory domain of S. aureus Efb (extracellular, fibrinogen-binding protein). We observed preferential binding by Ehp to, native and hydrolyzed C3 relative to fully active C3b and found that Ehp, formed a subnanomolar affinity complex with these various forms of C3 by, binding to its thioester-containing C3d domain. Site-directed mutagenesis, demonstrated that Arg(75) and Asn(82) are important in forming the Ehp.C3d, complex, but loss of these side chains did not completely disrupt Ehp/C3d, binding. This suggested the presence of a second C3d-binding site in Ehp, which was mapped to the proximity of Ehp Asn(63). Further molecular level, details of the Ehp/C3d interaction were revealed by solving the 2.7-A, crystal structure of an Ehp.C3d complex in which the low affinity site had, been mutationally inactivated. Ehp potently inhibited C3b deposition onto, sensitized surfaces by the alternative complement activation pathway. This, inhibition was directly related to Ehp/C3d binding and was more potent, than that seen for Efb-C. An altered conformation in Ehp-bound C3 was, detected by monoclonal antibody C3-9, which is specific for a neoantigen, exposed in activated forms of C3. Our results suggest that increased, inhibitory potency of Ehp relative to Efb-C is derived from the second, C3-binding site in this new protein. | ||
==About this Structure== | ==About this Structure== | ||
2NOJ is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [http://en.wikipedia.org/wiki/Staphylococcus_aureus Staphylococcus aureus]. Full crystallographic information is available from [http:// | 2NOJ is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [http://en.wikipedia.org/wiki/Staphylococcus_aureus Staphylococcus aureus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2NOJ OCA]. | ||
==Reference== | ==Reference== | ||
| Line 23: | Line 19: | ||
[[Category: protein-protein complex]] | [[Category: protein-protein complex]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 12:32:21 2008'' | ||
